Melatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine Tumours

Fanny Söderquist¹, Eva Tiensuu Janson², Annica J. Rasmusson³, Abir Ali², Mats Stridsberg⁴, Janet L. Cunningham¹*

¹ Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden, ² Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden, ³ Department of Medical Sciences, Clinical Pharmacology and Osteoporosis, Uppsala University, Uppsala, Sweden, ⁴ Department of Medical Sciences, Biochemical Endocrinology, Uppsala University, Uppsala, Sweden

* janet.cunningham@neuro.uu.se

Abstract

Background/Aims
Small intestinal neuroendocrine tumours (SI-NETs) are derived from enterochromaffin cells. After demonstrating melatonin in enterochromaffin cells, we hypothesized that SI-NETs may express and secrete melatonin, which may have an impact on clinical factors and treatment response.

Methods
Tumour tissue from 26 patients with SI-NETs, representing paired sections of primary tumour and metastasis, were immunohistochemically stained for melatonin and its receptors, MT₁ and MT₂. Plasma melatonin and immunoreactivity (IR) for melatonin, MT₁ and MT₂ in tumour cells were compared to other tumour markers and clinical parameters. Melatonin was measured at two time points in fasting morning plasma from 43 patients with SI-NETs.

Results
Melatonin IR was found in all SI-NETs. Melatonin IR intensity in primary tumours correlated inversely to proliferation index (p = 0.022) and patients reported less diarrhoea when melatonin IR was high (p = 0.012). MT₁ IR was low or absent in tumours. MT₂ expression was medium to high in primary tumours and generally reduced in metastases (p = 0.007). Plasma-melatonin ranged from 4.5 to 220.0 pg/L. Higher levels were associated with nausea at both time points (p = 0.027 and p = 0.006) and flush at the second sampling. In cases with disease stabilization or remission (n = 34), circulating melatonin levels were reduced in the second sample (p = 0.038).

Conclusion
Immunoreactive melatonin is present in SI-NETs. Circulating levels of melatonin in patients with SI-NETs are reduced after treatment. Our results are congruent with recent understanding of melatonin’s endocrine and paracrine functions and SI-NETs may provide a model for further studies of melatonin function.
Introduction

Small intestinal neuroendocrine tumours (SI-NETs) are tumours derived from enterochromaffin (EC) cells. These tumours are generally well differentiated with low proliferation rate and survival expectancy longer than for other NETs [1]. SI-NETs are generally sporadic although familial cases have been reported [2]. EC-cells and consequently SI-NETs are known to produce and secrete a number of bioactive agents including serotonin and tachykinins such as substance P and neurokinin A [3]. These hormones contribute to the “carcinoid syndrome”; a set of symptoms that include diarrhoea, cutaneous flush, bronchial constriction and carcinoid heart disease, which generally appear when the tumour has metastasized to the liver. Most patients present with disseminated disease and treatment is often focused on reduction of tumour burden, slowing tumour progression and ameliorating symptoms with primarily somatostatin analogues and/or interferon-alpha [4–6].

Melatonin, first isolated by Lerner et al, is an indoleamine, two enzymatic steps from serotonin, produced by the pineal gland and promotes sleep [7]. A replicated finding is lower peripheral evening or night-time melatonin levels in depressed patients compared to healthy controls [8]. Melatonin receptor agonists are now used in psychiatric care for treatment of sleeping disorders, depression and anxiety and may have potential for treating other disorders [9].

Melatonin also acts in an autocrine, paracrine and endocrine manner mediating a wide spectrum of regulatory metabolic functions, which includes glucose homeostasis and vascular effects [10]. Studies by Slominski et al have shown pathways for melatonin synthesis in human skin and melatonin may play a significant role in preserving skin barrier and in protection against UV-induced skin damage [11–13]. Melatonin can reduce toxicity and adverse side effects of cancer treatment and has also been shown to have independent oncostatic effects in various types of cancer [14].

We have recently described the expression of melatonin and its receptors, MT_1 and MT_2, in the normal human gastrointestinal (GI) tract and pancreas [15]. Expression of melatonin as well as MT_2 was found in EC-cells, but not MT_1. Melatonin in the GI-tract differs in circadian rhythm from pineal produced melatonin and varies in relation to fasting and food intake. Levels of melatonin in the gastrointestinal tissues greatly exceed serum levels [16]. In the GI-tract of animals, melatonin appears to act as a physiological antagonist of serotonin in regulating motility and it protects the mucosa by increasing bicarbonate secretion [17, 18]. Melatonin expression in SI-NETs is yet to be investigated.

Objectives

This study aimed to examine the immunohistochemical expression of melatonin and its receptors, MT_1 and MT_2, in SI-NETs in relation to proliferation index and local symptoms. Furthermore, we investigated levels of circulating melatonin in patients with SI-NETs in relation to symptoms and outcome measures.

Materials and Methods

Patient samples

Clinical data were collected retrospectively from electronic medical records for 52 patients with SI-NETs, diagnosed between 1976 and 2007 at the Laboratory of Pathology and Cytology and treated at the Department of Endocrine Oncology, Uppsala University Hospital in Sweden. Patients were included in plasma analyses based on availability of paired data from two sampling occasions (n = 43). Patients were included in immunohistochemical analyses based on availability of both primary and metastatic tissue, quality of tumour material and clinical data.
Seventeen patients were included in both parts of the study. The diagnosis of SI-NET was based on international recommendations for the classification of endocrine tumours. Plasma-chromogranin A (CgA), urinary 5-hydroxyindole acetic acid (U-5-HIAA), radiology and histopathological investigations were performed at diagnosis [19].

The data extracted from the medical records, from time of blood sampling or operation, included age at diagnosis, BMI, smoking history, diagnosis of diabetes, use of psychiatric drugs that potentially modify serotonin and/or melatonin levels (antidepressants, anti-anxiety drugs and medication for sleep disorders), U-5-HIAA and CgA. Smoking history was classified as current, past or no smoking history. Symptoms of diarrhoea, nausea and/or vomiting and flushing were also documented. Information of tumour grade was collected from the histopathological statement at the time of diagnosis for patients in plasma analyses. For patients included in the immunohistochemical analyses, Ki67 index was re-evaluated for each case on serial sections. The disease stage and clinical data were documented either at time of plasma sampling or time of operation for the respective patient groups.

For detailed patient characteristics see Table 1. All patients in the immunohistochemical analyses had disseminated disease at the time of surgery, for detailed tumour classification data see Table 2.

Immunohistochemistry (IHC) and microscopy assessments

Tissue specimens were fixed in 4% buffered formalin for 1–2 days, dehydrated, and embedded in paraffin wax. Sections, 4 μm thick, were attached to positively charged glass superfrost slides (Menzel-Gläser, Braunschweig, Germany), deparaffinized in xylene and rehydrated using decreasing concentrations of ethanol to distilled water. Antigen retrieval was performed using pressure cooker treatment for 10 minutes in citrate buffer pH 6. For MT1, sections were incubated for 30 minutes in 0.1% H2O2 to quench endogenous peroxidase, washed in phosphate-buffered saline (PBS), and then incubated with normal horse serum diluted 1:5 for 30 minutes. (Vector Laboratories, Burlingame, CA, USA). The sections were then incubated overnight at 4°C with a polyclonal goat anti-human MT1 antibody (Anti-MTR-1A, N-20, sc13179, Santa Cruz Biotechnology, Dallas, Texas, USA diluted 1:500). Sections were washed thrice in PBS and then incubated with biotinylated horse anti-goat antibody (BA-9500, Vector Laboratories Peterborough, United Kingdom). Thereafter, sections were incubated for 30 minutes with avidin-biotin–horseradish peroxidase (PK-6100, Vectastain Elite ABC kit, Vector Laboratories, Peterborough, United Kingdom). Rabbit anti-melanotin (0100–0203 AbD Serotec, Kidlington, UK, diluted 1:500), rabbit anti-melanotin receptor 1B (MT2) (ABIN122307, Antibodies-online GmbH, Aachen, Germany diluted 1:100), monoclonal mouse anti-serotonin (Clone 5HT-H209 DAKO Sweden AB, Stockholm, Sweden, diluted 1:100) and monoclonal mouse anti-human Ki67 (Clone MIB-1, DAKO, Glostrup, Denmark, diluted 1:100) antibodies were diluted in PBS with 1% bovine serum albumin (BSA). The DAKO EnVision™ systems for rabbit and for mouse (DAKO Sweden AB, Stockholm, Sweden) were used for antibody detection according to the manufacturer’s instructions. Diaminobenzidine (DAB) was used as chromogen. For visualization of nuclei, the sections were counterstained with Mayer’s haematoxylin.

Tumour material consisted of serial sections of primary tumours (n = 26) and metastases (n = 26). All specimens were coded and examined microscopically by transmitted light using Zeiss Axiophot microscope and Axiovision software (version SE64, Rel. 4.9.1, Carl Zeiss AB, Stockholm, Sweden) by three different observers, performed blinded at different occasions using both low (100–200x) and high magnification (400x) and images were acquired with a colour camera with the same illumination and the colour balance corrected. All tumour sections were subjectively assessed regarding a positive or negative expression for melatonin, serotonin,
Table 1. Clinical characteristics for patients submitted to analyses of plasma and tissue.

|                                | Tissue analyses (n = 26) | Plasma analyses (n = 43) |
|--------------------------------|--------------------------|--------------------------|
| **Age (years)**                |                          |                          |
|                                | 61 [42–86]               | 61 [26–79]               |
| **Sex**                        |                          |                          |
| female                         | 13                       | 23                       |
| male                           | 13                       | 20                       |
| **BMI (kg/m²)⁴**               |                          |                          |
|                                | 23.6 [14.9–31.8]         | 25.0 [14.9–41.9]         |
| **Smoking history**            |                          |                          |
| no                             | 15                       | 26                       |
| past                           | 9                        | 12                       |
| current                        | 2                        | 5                        |
| **Diabetes**                   |                          |                          |
|                                | 3                        | 5                        |
| **Psychiatric drugs**          |                          |                          |
| antidepressants                | 3                        | 6                        |
| anti-anxiety drugs             | 2                        | 5                        |
| sleeping pills                 | 5                        | 6                        |
| **WHO classification, stage**  |                          |                          |
| IIb                            | 0                        | 2                        |
| IIIa                           | 0                        | 0                        |
| IIIb                           | 6                        | 16                       |
| IV                             | 20                       | 25                       |
| **Tumour grade⁵**              |                          |                          |
| G1                             | 21                       | 31                       |
| G2                             | 5                        | 6                        |
| G3                             | 0                        | 0                        |
| **Metastases**                 |                          |                          |
| Lymph node                     | 26                       | 41                       |
| Liver                          | 20                       | 25                       |
| Distant⁶                       | 10                       | 9                        |
| **Carcinoid syndrome**         | 21                       | 37                       |
| **Treatment before analysis**  |                          |                          |
| Medical⁷                       | 14                       | 7                        |
| Surgery                        | 1                        | 22                       |
| Untreated                      | 12                       | 17                       |
| **Survival (months)⁸**         | 101 (79–122)             | 144 (122–166)            |

* BMI = Body Mass Index; Missing data for 3 patients in plasma analyses and for 2 patients in tissue analyses.

⁴ G1 Ki67 index <2%, G2 Ki67 index 3–20%, G3 Ki67 index >20%. Missing data for patients (n = 6).

⁵ Distant metastases: peritoneal carcinomatosis (n = 4), lung (n = 2), bone (n = 2), ovary (n = 1), breast (n = 1), pancreas (n = 1), orbita (n = 1).

⁶ Medical treatment includes interferon-alpha, somatostatin analogues or a combination of the two.

⁷ Mean (95% confidence interval), censored data for 2 patients in plasma analyses and for 5 patients in tissue analyses.

MT₁ and MT₂ as well as the intensity of the staining when positive. Immunoreactivity (IR) on sections was classified according to a scoring system including negative (0), weak (1), moderate (2) or strong (3). Very high correlation was found between the evaluations of different observers, the intraclass correlation coefficient, Cronbach’s Alpha, was 0.955 indicating high reliability. In the few cases when the observers assigned different scores, slides were evaluated together.
and consensus was reached. To further ensure reliability in scoring, sections were analysed using Image J software. The DAB-brown staining was identified using the Color Threshold plugin with the colour space set to HSB and the hue set to range 0–70. Median signal intensity in two tumour areas for each section was evaluated by FIJI/Image J software [20]. Three groups based on intensity scores were defined and labelled weak, moderate and strong (see Fig 1C and 1D and S1 Fig). When comparing manual scoring with the computerized scoring, Cronbach’s Alpha was 0.934.

Positive control sections from tissues known to express MT<sub>1</sub> and MT<sub>2</sub> (skin, pancreas) were used for comparison. In tumour sections assessed as negative, staining was present in control cells (epithelium, immune cells).

**Antibody specificity tests**

We have previously reported the antibody specificity tests and results [15]. In summary, control immunostaining included omission of the primary antisera and replacement of the primary antibody by non-immune serum at the same dilution as the primary antibody in question in the same diluent was performed for all antibodies. A neutralisation test was performed for melatonin antibodies by preincubation in saturated solutions of melatonin (0.1 mg/mL) or serotonin (0.1 mg/mL) in PBS with 1% BSA. Specificity tests using preincubation with corresponding peptides were also performed for the MT<sub>1</sub> and MT<sub>2</sub> antibodies using IHC. A 24-hour incubation of primary antiserum with the relevant peptide (sc-13179P, Santa Cruz Biotechnology, Dallas, Texas, USA and SP4391CP, Acris Antibodies GmbH, Herford, Germany, 10 nmol peptide per mL, diluted 1:100 antibody solution) was performed before application to the sections.

| Table 2. Biomarkers, symptoms, treatment and response at plasma sampling 1 and 2 in 43 patients. |
|----------------------------------------------------|------|-------|
| **Sampling 1** | **Sampling 2** |
| **Melatonin median [range]** | 26.0 [4.5–220.0] | 23.0 [8.9–90.7] |
| **CgA median [range]** | 8.4 [1.6–355.0] | 5.7 [1.7–121.0] |
| **U-5-HIAA median [range]** | 73.0 [10.0–1380.0] | 36.5 [10.0–1130.0] |
| **Clinical symptoms** | | |
| Diarrhoea | 30 | 25 |
| Nausea/vomiting | 11 | 10 |
| Flush | 25 | 16 |
| **Treatment** | | |
| INF | 4 | 38 |
| SOM | 5 | 18 |
| INF+SOM | 2 | 13 |
| Surgery | 22 | 16<sup>a</sup> |
| Untreated | 17 | 0 |
| **Treatment response** | | |
| Stable disease | | 18 |
| Regressive disease | | 16 |
| Progressive disease | | 9 |

<sup>a</sup> Only patients that underwent surgery between samplings are reported.

Abbreviations: CgA = chromogranin A, U-5-HIAA = urinary 5-hydroxyindoleacetic acid, INF = interferon-alpha, SOM = somatostatin analogues.

doi:10.1371/journal.pone.0164354.t002
Plasma analyses

Plasma samples were collected in the morning after an overnight fast at two occasions (sampling 1 and 2) and stored at -80°C. Treatment with surgery, interferon-alpha, somatostatin analogues or any combination of the three was documented for both time points. For three patients, there was no change in treatment between sampling 1 and 2. Response to treatment between samplings was classified as regression, stabilization or progression, according to radiological and/or biochemical response. Biochemical progression was defined as an increase in either CgA or U-5-IIIA by >25% and regression as a decrease by >50%. A specialist in radiology using computerized tomography and/or ultrasound evaluated radiological progression or regression of metastases. Patients with stabilization or tumour regression were compared to those with tumour progression in statistical analyses.

Plasma levels of melatonin were measured using competitive radioimmunoassay (Melatonin direct RIA, LDN, Norhorn, Germany), all samples were analysed at the same time using a kit from the same batch. Total coefficient of variation was less than 10%.

Fig 1. A–D. Microphotograph of SI-NETs illustrating expression of serotonin, melatonin and MT2. A) Serotonin in primary tumour, arrow indicating positive serotonin IR in EC-cell. B) Melatonin in the same tumour, arrow indicating strong positive melatonin IR in immune cell. C) Strong MT2 IR in primary tumour, arrow indicating positive MT2 IR in EC-cell. D) Weak MT2 IR in metastasis from the same patient as C. Magnification 200 times.

doi:10.1371/journal.pone.0164354.g001
Statistical analyses

Data was stored in an Access database and analysed using the statistical program package SPSS 21.0 (SPSS Inc., Chicago, IL, USA). Statistical analyses were conducted separately for the two groups of patients; those where histopathological specimens were available (n = 26) and those where plasma samples were collected (n = 43). The cohorts were not compared to each other. Patient characteristics were presented in descriptive statistical analyses. Survival was calculated from time of diagnosis to death. For patients still alive, time of diagnosis until present date was used to calculate survival. Five patients were lost to follow-up and they were censored in survival analyses.

For statistical analyses of differences between the intensity of IR in primary tumours and metastases and for change in biomarker response between samplings, Wilcoxon Signed Ranks Test was used. Spearman’s test was used for analyses of correlations between IR or plasma melatonin and clinical parameters. The Mann-Whitney U test was used to look for sex differences in circulating levels of melatonin in plasma. Survival analyses were performed using the Mantel-Cox log rank test.

Results are presented as median [range] unless otherwise stated. A p-value less than 0.05 was considered significant. Effect size for the Wilcoxon Signed Ranks test was calculated using the formula $r = Z/(\sqrt{n})$ [21].

Ethics statement

The study was approved by the local ethics committee of the Uppsala University Hospital (Dnr: 2007/143 and 2007/143/1 GK 2012-09-14) and all included patients signed an informed consent.

Results

Antibody specificity tests

Preincubation of melatonin antibodies with saturated serotonin solution marginally blocked the melatonin immunostaining (see S2 Fig and S3 Fig). Only partial overlap between melatonin and serotonin is seen in co-localisation studies [15] and comparison of serial section, (see S4 Fig). Staining with melatonin, MT$_1$ and MT$_2$ antibodies were completely blocked by preincubation with the respective antigens (see S5 Fig and S6 Fig).

Expression of melatonin IR in SI-NETs and correlation to clinical parameters

Melatonin IR was found in all primary tumours (n = 26) and metastases (n = 26), see Table 3. IR intensity in primary tumours was weak in 6 cases, medium in 11 cases and strong in 9 cases. In metastases, weak IR was seen in 10 cases, while 9 were medium and 7 showed strong IR. No significant difference in melatonin IR intensity between primary tumours and metastases was found ($r = 0.29; p = 0.134$). Immunohistochemical staining is illustrated in Fig 1.

A negative relationship was found between melatonin IR in primary tumours and the proliferation marker Ki67 ($r = -0.446; p = 0.022$). Melatonin IR in primary tumours as well as in metastases showed an inverse correlation to diarrhoea ($r = -0.484; p = 0.012$ and $r = -0.398; p = 0.044$, respectively) but for other symptoms reported, no significant correlations were found. There were no significant correlations between melatonin IR and sex, BMI, diabetes, use of psychiatric drugs or survival.
Expression of MT<sub>1</sub>IR and MT<sub>2</sub>IR in SI-NETs and correlation to clinical parameters

MT<sub>1</sub> IR was low or absent in the majority of sections studied. In primary tumours, 21 sections were negative and 5 sections showed weak IR. In metastases, 20 were negative and 6 sections were weakly positive (see Table 3). Positive MT<sub>1</sub> IR was found in the brush border of the epithelium, which served as an internal positive control. No significant difference in MT<sub>1</sub> IR between primary tumours and metastases was found (r = 0.088; p = 0.655). MT<sub>1</sub> IR in primary tumours showed a significant positive correlation for the symptoms of diarrhoea (r = 0.418; p = 0.034), as well as for nausea and/or vomiting (r = 0.732; p = 0.00002). All sections positive for MT<sub>1</sub> IR were from female patients and the sex difference was statistically significant for both primary tumours (r = -0.488; p = 0.011) and metastases (r = -0.548; p = 0.004). No significant correlation between MT<sub>1</sub> IR and flush, BMI, diabetes, use of psychiatric drugs, Ki67 Index or survival was found.

MT<sub>2</sub> IR was positive in all 26 sections from primary tumours, 7 sections were weakly stained, 14 medium and 5 sections showed strong IR intensity. In metastases, 2 sections were negative, 13 weakly stained, 8 medium and 3 strongly positive. Intensity of MT<sub>2</sub> IR was generally lower in metastases than in primary tumours (r = 0.53; p = 0.007). Positive expression for MT<sub>2</sub>IR in tumour sections is illustrated in Fig 1. No significant association between MT<sub>2</sub> IR and clinical parameters including sex, symptoms of flush, diarrhoea, or nausea and/or vomiting, BMI, use of psychiatric drugs, Ki67 Index or survival was found.

Table 3. Expression of melatonin (Mel), receptors (MT<sub>1</sub> and MT<sub>2</sub>) and serotonin (Ser) in primary tumours and metastases assessed by immunohistochemistry. Difference (p-value) in expression between primary tumours (n = 26) and metastases (n = 26).

| Antibody | IR      | Primary tumour (n = 26) | Metastasis (n = 26) | P value<sup>a</sup> |
|----------|---------|------------------------|---------------------|--------------------|
| Melatonin| Positive IR | 100%                   | 100%                | 0.134              |
|          | Weak    | 6                      | 10                  |                    |
|          | Medium  | 11                     | 9                   |                    |
|          | Strong  | 9                      | 7                   |                    |
| MT<sub>1</sub> | Positive IR | 19%                   | 23%                 | 0.655              |
|          | Negative | 21                    | 20                  |                    |
|          | Weak    | 5                      | 6                   |                    |
| MT<sub>2</sub> | Positive IR | 100%                   | 92%                 | 0.007              |
|          | Negative | 0                      | 2                   |                    |
|          | Weak    | 7                      | 13                  |                    |
|          | Medium  | 14                     | 8                   |                    |
|          | Strong  | 5                      | 3                   |                    |
| Serotonin | Positive IR | 96%                   | 100%                | 0.206              |
|          | Negative | 1                      | 0                   |                    |
|          | Weak    | 0                      | 4                   |                    |
|          | Medium  | 5                      | 4                   |                    |
|          | Strong  | 20                     | 18                  |                    |

<sup>a</sup> Wilcoxon Signed Ranks Test

IR = Immunoreactivity

doi:10.1371/journal.pone.0164354.t003
Expression of serotonin IR in SI-NETs

All tumours with exception of one primary tumour expressed serotonin IR. The majority showed strong IR, in primary tumours \((n = 20)\) and in metastases \((n = 21)\). The remaining sections showed medium IR. No correlations between serotonin IR and melatonin IR, Ki67 Index, or carcinoid syndrome symptoms were found.

Analyses of plasma samples from patients with SI-NETs

Median plasma melatonin level at the first sampling was 26.0 pg/L \([4.5–220.0]\) and at the second sampling 23.0 pg/L \([8.9–90.7]\), see Table 2. A wider range of values of circulating melatonin was seen at the first sampling occasion compared to the second. Age did not correlate with melatonin values at either occasion \((r = -0.129, p = 0.409; r = 0.074, p = 0.636)\). In patients with disease stabilization or regression at the second sampling, melatonin levels were reduced at the second sampling \((r = 0.356; p = 0.038)\) and the largest reductions were seen in patients with the highest levels of melatonin at the first sampling. The tumour markers CgA and U-5-HIAA were also reduced in these patients \((r = 0.731; p = 0.00003 \text{ and } r = 0.828; p = 0.000003)\).

A significant sex difference in levels of circulating melatonin was noted at both sampling occasions, with higher levels in women than in men \((r = 0.46; p = 0.003 \text{ and } r = 0.39; p = 0.010, \text{ respectively})\). There was no difference between men and women in treatment response. A positive relationship between plasma melatonin levels and symptoms of nausea and/or vomiting was found at both time points \((r = 0.337, p = 0.027 \text{ and } r = 0.413; p = 0.006)\) and at the second time point there was also a correlation to flush \((r = 0.353; p = 0.020)\). There was no significant correlation at either of the sampling occasions between plasma levels of melatonin and use of psychiatric drugs, BMI, tumour grade or survival.

Discussion

This is the first study to demonstrate expression of immunoreactive melatonin in SI-NETs. Ubiquitous expression of melatonin in SI-NETs agrees with earlier findings of melatonin IR and gene expression of the enzymes needed for the production of melatonin from serotonin, arylalkylamine N-acetyltransferase and acetylserotonin O-methyltransferase, in EC-cells [15]. The expression of immunoreactive melatonin in SI-NETs correlates to a lower proliferation index in this study, which is in agreement with the anti-neoplastic effects of melatonin described in many studies. For example, anti-proliferative effects were demonstrated for melatonin in murine colon cancer [22]. Melatonin induced caspase activity and apoptosis in human malignant lymphoid cell lines [23] and caused cell cycle arrest in HepG2 human hepatocarcinoma cells [24]. In neural and blood cells and other normal tissues, however, melatonin promotes cell survival by reducing apoptosis through decreased activity of caspase-9 and -3 [25–27]. It is possible that melatonin contributes to the paradoxical clinical phenotype of many SI-NETs where low proliferation and apoptosis rates but nonetheless malignant behaviour is described [28].

Previous studies have identified oncostatic effects of melatonin mediated by the \(\text{MT}_1\) receptor. For instance a recent study in colorectal adenocarcinoma showed reduced expression of \(\text{MT}_1\) when compared to adjacent normal tissue and it was speculated that \(\text{MT}_1\) may mediate anti-tumourigenic effects [29]. \(\text{MT}_1\) IR was low or absent in both primary and metastatic tissue which is in line with a model where tumour cells are able to proliferate despite elevated levels of melatonin. Binding of melatonin to the \(\text{MT}_1\) receptor has been reported to up-regulate cyklin dependent kinase inhibitor gene \((\text{CDKN1B/p27})\) in prostate cancer [30]. Interestingly, the tumour suppressor p27 is highly expressed in most SI-NETs; however, mutations in the
gene encoding p27, leading to dysregulation of the cell cycle, have been proposed as an underlying genomic mechanism in the pathogenesis of SI-NETs [31, 32].

Immunoreactivity for the MT$_2$ receptor, on the other hand, was identified in all tumours studied; however, the intensity of MT$_2$ IR was much lower in metastases than in primary tumours. MT$_2$ intensity did not correlate to Ki67 Index. This loss of MT$_2$ receptor expression could represent decreased sensitivity to anti-tumourigenic effects of melatonin and merits further investigation.

A wide range of values for morning plasma melatonin was found in patients with SI-NETs. Surprisingly these values were not correlated with age. Although melatonin is produced in different organs, the largest source of circulating melatonin is usually the pineal gland during nocturnal hours [33]. Melatonin production is drastically reduced with age and was expected to be lower in the study population where the median age is 61. After treatment (interferon-alpha, somatostatin, surgery alone or in combination) levels of melatonin, CgA and U-5HIAA were reduced in patients with tumour regression or stabilization, which indicates that, a reduction of tumour size and/or activity results in a lower amount of circulating melatonin. In relation to clinical parameters, high levels of circulating melatonin were significantly correlated to the symptoms of nausea and/or vomiting. A slower gastrointestinal transit time could hypothetically cause nausea, which is in agreement with the proposed actions of melatonin in regulation of gastrointestinal motility [16]. Related to this, the immunohistochemical expression of melatonin correlated inversely to the symptom of diarrhoea, indicating less trouble with diarrhoea when a high intensity of melatonin IR was found in the tumour. Melatonin is a small lipophilic compound that diffuses easily through cell membranes and quickly accesses different tissues allowing for both paracrine and endocrine actions. The functional effects of melatonin in the gastrointestinal tract in humans are still being explored and animal studies have shown ambiguous and dose-dependent results regarding the effect of melatonin on motility [17, 34]. Our findings support earlier claims for a future role for melatonin in the therapy for diarrhoeal diseases for example ulcerative colitis and irritable bowel syndrome [35]. Circulating levels of melatonin at the second sampling occasion also correlated to the symptom of flush. Flush in the carcinoid syndrome is primarily associated with the release of serotonin and tachykinins [36], but melatonin has also been shown to have vasoactive effects [37].

We found a sex difference, with higher circulating levels of melatonin in the females than in the males, which is in agreement with previous findings of analyses of melatonin in overnight urine [38]. Besides sex, a wide variety of factors could influence gastrointestinal melatonin e.g. age [39], antidepressant medication [40] and BMI [41]. We did not find associations to these factors. It is possible that other confounding factors, yet to be identified, also affect circulating levels of melatonin.

The data from medical records was collected retrospectively, which limits the possible analyses that can be performed. There was no correlation between levels of melatonin and the use of antidepressants, anti-anxiety drugs or medication for sleeping disorders. Low melatonin is associated with sleeping disorders and other psychiatric conditions [8]. Theoretically, therapy that reduced melatonin levels may increase psychiatric symptoms and the psychiatric effects of hypermelatoninism are unknown. A study specifically designed to capture psychiatric symptoms is necessary to further explore these issues.

**Conclusions**

SI-NETs display immunoreactive melatonin and in patients with SI-NETs, levels of melatonin in plasma are reduced after treatment. In a subgroup of patients, circulating melatonin is associated with clinical symptoms with nausea and flush via endocrine or paracrine mechanisms.
We found that patients with high tumour expression of immunoreactive melatonin, in addition to less diarrhoea, had lower tumour proliferation. Furthermore, the expression of the melatonin receptor MT\textsubscript{2} was down regulated in metastases, which could indicate reduced sensitivity to melatonin signalling as important for tumour progression. These findings are congruent with recent understanding of melatonin’s biological functions in animal models and SI-NETs may provide a model for further studies of melatonin function.

**Supporting Information**

S1 Fig. Intensity scoring for melatonin immunohistochemistry. Representative examples of melatonin immunohistochemistry intensities of tumour tissue scored using both manual and computerised methods, weak (A), moderate (B) and strong (C).

(TIF)

S2 Fig. Melatonin antibody neutralisation test. Melatonin immunohistochemistry of normal human rectal epithelium stained using rabbit-anti melatonin antibody 0100–0203 (A). Melatonin immunohistochemistry of a consecutive section where antibody was pre-incubated with 0.1 mg/mL melatonin to ensure antibody specificity (B).

(TIF)

S3 Fig. Melatonin antibody cross-reactivity with serotonin. Melatonin immunohistochemistry of normal ileal epithelium stained using rabbit-anti melatonin antibody 0100–0203 (A). Melatonin immunohistochemistry of a consecutive section where antibody was pre-incubated with 0.1 mg/mL serotonin to ensure antibody specificity (B). Serotonin immunohistochemistry of consecutive section stained using anti-serotonin antibody 5HT-H209 (C). Arrowheads indicate enterochromaffin cells.

(TIF)

S4 Fig. Different staining patterns for melatonin and serotonin on consecutive sections. Melatonin immunohistochemistry of small intestinal neuroendocrine tumour stained using rabbit-anti melatonin antibody 0100–0203 (A). Serotonin immunohistochemistry of a consecutive section stained using anti-serotonin antibody 5HT-H209 (B). Arrowheads indicate cluster of tumour cells.

(TIF)

S5 Fig. Melatonin receptor 1 (MT1) antibody neutralisation test. Immunohistochemistry of normal ileal epithelium tissue stained using MT1 antibody sc13179 (A). Immunohistochemistry of a consecutive section where the antibody was pre-incubated with the corresponding peptide sc-13179P (B).

(TIF)

S6 Fig. Melatonin receptor 2 (MT2) antibody neutralisation test. Immunohistochemistry of normal ileal epithelium tissue stained using MT2 antibody ABIN122307 (A). Immunohistochemistry of a consecutive section where the antibody was pre-incubated with the corresponding peptide SP4391CP (B).

(TIF)

**Acknowledgments**

The authors thank Åsa Forsberg, laboratory technician for excellent technical assistance, and Hans Arinell, statistician at the Department of Neuroscience and Psychiatry for his assistance in
the statistical analysis of the data. We also thank Jeremy Adler at the SciLife BioVis Facility, Uppsala, for assistance in performing the ImageJ analysis.

**Author Contributions**

Conceptualization: FS JLC.

Data curation: FS JLC ETJ.

Formal analysis: FS JLC AR MS AA.

Funding acquisition: JLC.

Methodology: JLC ETJ MS AR AA.

Project administration: JLC.

Supervision: JLC.

Validation: AR.

Visualization: FS JLC AR.

Writing – original draft: FS JLC.

Writing – review & editing: FS JLC AR ETJ MS AA.

**References**

1. Janson ET, Sarbye H, Welin S, Federspiel B, Grenbaek H, Hellman P, et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2014; 53 (10):1284–97. Epub 2014/08/21. doi: 10.3109/0284186X.2014.941999 PMID: 25140861.

2. Cunningham JL, Diaz de Stahl T, Sjöblom T, Westin G, Dumanski JP, Janson ET. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes Cancer. 2011; 50(2):82–94. doi: 10.1002/gcc.20834 PMID: 21104784.

3. Turner GB, Johnston BT, McCance DR, McGinty A, Watson RG, Patterson CC, et al. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut. 2006; 55 (11):1586–91. doi: 10.1136/gut.2006.092320 PMID: 16556667; PubMed Central PMCID: PMCPMC1860112.

4. Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014; 371(16):1556–7. Epub 2014/10/16. doi: 10.1056/NEJMcl409757 PMID: 25317881.

5. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27(28):4656–63. Epub 2009/08/26. doi: 10.1200/JCO.2009.22.8510 PMID: 19704057.

6. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997; 8(7):685–90. Epub 1997/07/01. PMID: 9296223.

7. Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of Melatonin, the Pineal Gland Factor That Lightens Melanocytes. J Am Chem Soc. 1958; 80(10):2587–. doi: 10.1021/Ja01543a060 PMID: WOS:A1958WB38500060.

8. Malhotra S, Sawhney G, Pandhi P. The therapeutic potential of melatonin: a review of the science. MedGenMed: Medscape general medicine. 2004; 6(2):46. Epub 2004/07/22. PMID: 15266271; PubMed Central PMCID: PMC1395802.

9. Laudon M, Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014; 15(9):15924–50. Epub 2014/09/11. doi: 10.3390/ijms150915924 PMID: 25207602; PubMed Central PMCID: PMC4200764.

10. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Molecular and cellular endocrinology. 2012;
11. Slominski A, Pisarchik A, Semak I, Sweatman T, Wortsman J, Szczesniakowski A, et al. Serotoninergic and melatoninergic systems are fully expressed in human skin. FASEB J. 2002; 16(8):896–8. Epub 2002/06/01. doi: 10.1096/fj.01-0952fje PMID: 12039872.

12. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J. 2005; 19(2):176–94. Epub 2005/01/29. doi: 10.1096/fj.04-2079rev PMID: 15677341.

13. Slominski AT, Kleszczynski K, Semak I, Janjetovic Z, Zmijewski MA, Kim TK, et al. Local melatoninergic system as the protector of skin integrity. Int J Mol Sci. 2014; 15(10):17705–32. Epub 2014/10/02. pii: 10.3390/ijms151017705 PMID: 25272227; PubMed Central PMCID: PMC4227185.

14. Xin Z, Jiang S, Jiang P, Yan X, Fan C, Di S, et al. Melatonin as a treatment for gastrointestinal cancer: a review. J Pineal Res. 2015; 58(4):375–87. Epub 2015/03/11. doi: 10.1111/jpi.12227 PMID: 25752643.

15. Söderquist F, Hellström PM, Cunningham JL. Human gastrointestinal expression of melatonin and its receptors MT1 and MT2. PloS one. 2015; 10(3):e0120195. doi: 10.1371/journal.pone.0120195 PMID: 25822611; PubMed Central PMCID: PMC4378860.

16. Ellis PD. The essential guide to effect sizes: An introduction to statistical power, meta-analysis and the interpretation of research results: Cambridge : Cambridge University Press.; 2010.

17. Xin Z, Jiang S, Jiang P, Yan X, Fan C, Di S, et al. Melatonin as a treatment for gastrointestinal cancer: a review. J Pineal Res. 2015; 58(4):375–87. Epub 2015/03/11. doi: 10.1111/jpi.12227 PMID: 25752643.

18. Bubenik GA. Thirty four years since the discovery of gastrointestinal melatonin. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. 2008; 59 Suppl 2:33–51. Epub 2008/10/01. PMID: 18812627.

19. Thor PJ, Krolczyk G, Gil K, Zurowski D, Nowak L. Melatonin and serotonin effects on gastrointestinal motility. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. 2007; 58 Suppl 6:97–103. Epub 2008/03/28. PMID: 18212403.

20. Sjöblom M, Flemstrom G. Melatonin in the duodenal lumen is a potent stimulant of mucosal bicarbonate secretion. J Pineal Res. 2003; 34(4):288–93. Epub 2003/03/29. PMID: 12662352.

21. O¨ berg K, Åkerstrom G, Rindi G, Jelic S, Group EGW. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v223–7. Epub 2010/06/29. doi: 10.1093/annonc/mdq192 PMID: 20555086.

22. Martin-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andres O, Gonzalez P, Gonzalez-Gallego J. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res. 2008; 45(4):532–40. Epub 2008/11/18. JPI641 [pii] doi: 10.1111/j.1600-079x.2008.00641.x PMID: 19012662.

23. Das A, McDowell M, Pava MJ, Smith JA, Reiter RJ, Woodward JJ, et al. The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors. J Pineal Res. 2010; 48(2):157–69. Epub 2010/01/20. JPI739 [pii] doi: 10.1111/j.1600-079x.2009.00739.x PMID: 20082663; PubMed Central PMCID: PMC2862889.

24. Espino J, Bejarano I, Redondo PC, Rosado JA, Barriga C, Reiter RJ, et al. Melatonin reduces apoptosis induced by calcium signaling in human leukocytes: Evidence for the involvement of mitochondria and Bax activation. J Membr Biol. 2010; 233(1–3):105–18. Epub 2010/02/06. doi: 10.1007/s00232-010-9320-0 PMID: 2010848.

25. Espino J, Bejarano I, Ortiz A, Lozano GM, Garcia JF, Pariente JA, et al. Melatonin as a potential tool against oxidative damage and apoptosis in ejaculated human spermatozoa. Fertil Steril. 2010; 94(5):1915–7. Epub 2010/02/16. S0015-0282(09)04341-6 [pii] doi: 10.1016/j.fertnstert.2009.12.082 PMID: 20152967.

26. Cunningham JL, Grimalius L, Sundin A, Agarwal S, Janson ET. Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies...
patients with a poorer prognosis. Acta oncologica. 2007; 46(6):747–56. Epub 2007/07/27. 780592758 [pii] doi: 10.1080/02841860701218659 PMID: 17653896.

29. Nemeth C, Humpeler S, Kallay E, Mesteri I, Svoboda M, Rogelsperger O, et al. Decreased expression of the melatonin receptor 1 in human colorectal adenocarcinomas. J Biol Regul Homeost Agents. 2011; 25(4):531–42. Epub 2012/01/06. 5 [pii]. PMID: 22217986.

30. Shiu SY, Leung WY, Tam CW, Liu VW, Yao KM. Melatonin MT(1) receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via constitutively active nuclear factor kappa B (NF-kappaB): potential implications on prostate cancer chemoprevention and therapy. Journal of pineal research. 2012. Epub 2012/08/04. doi: 10.1111/j.1600-079X.2012.01026.x PMID: 22856547.

31. Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013; 45(12):1483–6. Epub 2013/11/05. doi: 10.1038/ng.2821 PMID: 24185511; PubMed Central PMCID: PMC4239432.

32. Canaves G, Azzoni C, Pizzi S, Corleto VD, Pasquali C, Davoli C, et al. p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum Pathol. 2001; 32(10):1094–101. Epub 2001/10/27. S0046817701019025 [pii]. PMID: 11679944.

33. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007; 42(1):28–42. Epub 2007/01/03. doi: 10.1111/j.1600-079X.2006.00407.x PMID: 17198536.

34. Delagrange P, Atkinson J, Boutin JA, Casteilla L, Lesieur D, Misslin R, et al. Therapeutic perspectives for melatonin agonists and antagonists. J Neuroendocrinol. 2003; 15(4):442–8. Epub 2003/03/08. PMID: 12622848.

35. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci. 2002; 47(10):2336–48. Epub 2002/10/25. PMID: 12395907.

36. Klöppel G, Perren A, Heitz PJ. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004; 1014:13–27. Epub 2004/03/22. PMID: 15153416.

37. Masana MI, Doolen S, Ershahin C, Al-Ghoul WM, Duckles SP, Dubocovich ML, et al. MT(2) melatonin receptors are present and functional in rat caudal artery. J Pharmacol Exp Ther. 2002; 302(3):1295–302. Epub 2002/08/17. PMID: 12183692.

38. Wetterberg L, Bratlid T, von Knorring L, Eberhard G, Yuwiler A. A multinational study of the relationships between nighttime urinary melatonin production, age, gender, body size, and latitude. European archives of psychiatry and clinical neuroscience. 1999; 249(5):256–62. Epub 1999/12/11. PMID: 10591991.

39. Waldhauser F, Weiszenczinger G, Tatzer E, Gisinger B, Waldhauser M, Schemper M, et al. Alterations in nocturnal serum melatonin levels in patients with growth and aging. J Clin Endocrinol Metab. 1988; 66(3):648–52. Epub 1988/03/01. doi: 10.1210/jcem-66-3-648 PMID: 3350912.

40. Carvalho LA, Gorenstein C, Moreno R, Pariante C, Markus RP. Effect of antidepressants on melatonin metabolite in depressed patients. Journal of psychopharmacology. 2009; 23(3):315–21. doi: 10.1177/0269881108098781 PMID: 18562432.

41. Brambilla F, Fraschini F, Esposti G, Bossolo PA, Marelli G, Ferrari E. Melatonin circadian rhythm in anorexia nervosa and obesity. Psychiatry research. 1988; 23(3):267–76. PMID: 3387501.